Asia Tech Wire (July 24) -- Chinese 3D printing company Triastek Inc. and German pharmaceutical company BioNTech SE will develop oral RNA drugs based on 3D printing technology.

Triastek announced Tuesday that it has entered into a research collaboration and platform technology license agreement with BioNTech.

Under the agreement, the two companies will develop oral RNA drugs based on 3D printing technology.

Triastek said the collaboration aims to deliver a breakthrough therapy that addresses "unmet medical needs in an easy to administer oral formulation."

Under the terms of the agreement, the Chinese company will receive an upfront payment of $10 million and may receive development, regulatory and commercial milestone payments potentially totaling over $1.2 billion as well as tiered royalties on potential future product sales.